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Abstract
This paper focuses on the problem of modeling and estimating interaction effects be-
tween covariates and a continuous treatment variable on an outcome, using a simple and
intuitive single-index regression approach. The primary motivation is to estimate an optimal
individualized dose rule in an observational study. To model possibly nonlinear interac-
tion effects between patients’ covariates and a continuous treatment variable, we employ a
two-dimensional penalized spline regression on an index-treatment domain, where the in-
dex is defined as a linear projection of the covariates. The method is illustrated using two
applications as well as simulation experiments. A unique contribution of this work is in
the parsimonious (single-index) parametrization specifically defined for the interaction effect
term.
Keywords: Single-index model, individualized dose rules, tensor product P-splines, heterogeneous
dose effects
1 Introduction
In precision medicine, a primary goal is to characterize individuals’ heterogeneity in treatment
responses so that individual-specific treatment decisions can be made (Murphy, 2003; Robins,
2004). Most work on developing methods for individualized treatment decisions has focused on a
finite number of treatment options. The focus of this paper is to develop individualized treatment
decision methodology in the realm of a continuous treatment. Specifically, we consider a semipara-
metric regression approach for developing optimal individualized dosing rules based on baseline
patient characteristics. Often in clinical practice, the maximum dose that a patient can tolerate
is the most effective one. However, there are situations where this is not the case. In the example
∗This work was supported by National Institute of Health (NIH) grant 5 R01 MH099003.
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section below, we present a study of warfarin (an anticoagulant), where too high doses lead to
severe bleeding and thus the highest dose is not the the optimal dose. In finding the optimal dose,
there is an essential non-monotone and nonlinear relationship that needs to be accounted for. A
similar case is with insulin for controlling blood glucose levels.
To establish notation, let X = (X1, . . . , Xp)
> ∈ X be the set of baseline covariates, Y ∈ R be
the outcome variable, and A ∈ A denote the dose. Without loss of generality, we assume that
a larger value of the outcome Y is better. The goal is then to find an optimal individualized
dose rule f : X 7→ A such that for a patient with covariate X, the dose assignment A = f(X)
maximizes the expected response, the so-called value function:
V(f) = E[E[Y |A = f(X), X]]. (1)
In settings in which the treatment can be administered at continuous doses (i.e., when A is an
interval), Chen et al. (2016) proposed to optimize the individualized dosing rule f by maximizing
an empirical version of a modified value function (1), optimized under the framework of outcome
weighted learning (Zhao et al., 2012). In this paper, we consider a regression-based approach
to optimizing f that uses a semiparametric regression model for E[Y |A,X]. While the outcome
weighted learning approach of Chen et al. (2016) is highly appealing, regression-based approaches,
particularly the proposed semi-parametric models, have the advantage of being simple, easy to
implement, and readily interpretable.
It is straightforward to see that, given X, the optimal dose fopt(X) (i.e., that which maximizes
the value function (1)) is
fopt(X) = argmax
a∈A
m(a,X), (2)
where m(a,X) = E[Y |A = a,X]. If we estimate m(a,X) with mˆ(a,X), then the optimal rule fopt
in (2) can be approximated as
fˆ(X) = argmax
a∈A
mˆ(a,X). (3)
Methodologies for optimizing individualized treatment rules f in the literature are developed
almost exclusively for the cases in which the treatment variable A is binary or discrete-valued.
Regression-based methodologies typically approximate the function fopt in (2) by first estimating
the treatment a-specific mean response functions m(a,X) to obtain a treatment decision rule, i.e.,
the left-hand side of (3) (e.g., Qian and Murphy, 2011; Zhang et al., 2012; Gunter et al., 2011;
Lu et al., 2013). In particular, Qian and Murphy (2011) show that the optimal individualized
treatment rules, in terms of maximizing the expected treatment response (1), depends only on
the interaction between treatment A and covariates X, and not on the main effects of X present
in the mean response functions m(a,X), a ∈ A. For regression-based methodologies, a successful
estimation of the function fopt in (2) boils down to efficiently estimating the A-by-X interaction
effects on the mean response function. In this paper, we consider a semi-parametric regression
model that is useful for estimating such interactions in the case where A is a continuous dose
variable.
2
2 Models
Our goal is to provide an interpretable and flexible approach to modeling and estimating the A-
by-X interaction effects on Y . To achieve this goal, we consider the following additive single-index
model:
E[Y |X,A] = µ(X) + g(β>X,A) (4)
where µ(X) represents an unspecified main effect of X, and g(β>X,A) models the A-by-X inter-
action effects. Here, g(·, ·) is an unspecified smooth two-dimensional surface link function of the
variable A and a single index β>X. We shall call model (4) a single-index model with a surface-link
(SIMSL). We restrict β ∈ Θ := {β = (β1, . . . , βp)> ∈ Rp : ‖β‖2 = 1, β1 > 0}, as β in (4) is only
identifiable up to a scale constant without further constraint, due to the unspecified nature of g.
Without loss of generality, we assume E[Y ] = 0 and E[µ(X)] = 0, and E[g(β>X,A)] = 0 (where
the expectation is with respect to X and A), i.e., each of the additive components in model (4) has
mean 0, and that µ(X) and g(β>X,A) have finite variances. That is, let H1 and H(β)2 (for a fixed
β ∈ Θ) denote the Hilbert spaces of measurable functions µ(X) on X and measurable functions
g(β>X,A) on (β>X,A) (which depend on β), respectively, and we assume µ ∈ H1 and g ∈ H(β)2 .
To eliminate the confounding of the interaction effect with the main effect in (4), we impose
an identifiability constraint on the smooth g ∈ H(β)2 :
E
[
g(β>X,A)|X] = 0, a.s. (X) X ∈ X , β ∈ Rp (5)
which separates the X main effect term µ(X) from the A-by-X interaction effect term g(β>X,A) in
the SIMSL (4) and thus defines the term g(β>X,A) to correspond to a “pure” A-by-X interaction.
Under the SIMSL (4), the optimal individualized dose rule, fopt, is specified as: fopt(X) =
argmax
a∈A
g(β>X, a). Therefore, in terms of estimating fopt in (2), our modeling focus is on esti-
mating g and β. In this regards, the unspecified function µ in (4) is a “nuisance” component. For
an optimal coefficient vector β associated with the term g(β>X,A), the shape of the function g
captures a nonlinear interactive structure between A and β>X, and the heterogeneous dose effects.
Using the constrained least squares framework, the right-hand side of (4), subject to constraint
(5), can be optimized by solving:
(µ∗, g∗, β∗) = argmin
µ∈H1,g∈H(β)2 ,β∈Θ
E
[
(Y − µ(X)− g(β>X,A))2]
subject to E
[
g(β>X,A)|X] = 0. (6)
Constraint (5) ensures that E
[
µ(X)g(β>X,A)
]
= E
[
µ(X)E[g(β>X,A)|X]] = 0 (where we
apply the iterated expectation rule to condition on X), which implies
µ(X) ⊥ g(β>X,A). (7)
The orthogonality (7) implies that the optimization for µ∗ and (g∗, β∗) in the optimization (6)
can be performed separately, without iterating between the two optimization procedures. That is,
first we can solve for the main effect:
µ∗ = argmin
µ∈H1
E
[
(Y − µ(X))2]. (8)
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Then we can solve (for the interaction effect):
(g∗, β∗) = argmin
g∈H(β)2 ,β∈Θ
E
[
(Y˜ − g(β>X,A))2]
subject to E
[
g(β>X,A)|X] = 0, (9)
where Y˜ = Y − µˆ∗(X) is the residual from the (main effect) fit (8), in which µˆ∗ denotes some
estimate of µ∗ in (8). The residual Y˜ on the right-hand side of (9) can be replaced simply by the
original variable Y , since taking µˆ∗ = 0 does not change the minimizer (g∗, β∗) on the left-hand
side of (9), due to orthogonality (7) between the two additive terms in model (4).
The optimal individualized dose rule, fopt, is then fitted as: fˆ(X) = argmax
a∈A
gˆ∗(βˆ
∗>X, a),
where we estimate (g∗, β∗) with (gˆ∗, βˆ∗). The interaction effect optimization approach (9) to
estimating fopt in (2) is appealing, since, due to orthogonality (7), misspecification of the function
µ in (8), for example, setting µˆ∗ = 0 (which is an extreme case), does not affect specification of
g∗ and β∗ on the left-hand side of (9).
We focus on solving (9) as our primary focus is on estimating the A-by-X interaction effect.
For each fixed β, since the function g(β>X,A) depends on the covariates X ∈ X only through
the 1-dimensional projection β>X, E
[
g(β>X,A)|X] = E [g(β>X,A)|β>X]. Then, for each fixed
β ∈ Θ, the following constraint on g ∈ H(β)2 ,
E
[
g(β>X,A)|β>X] = 0, X ∈ X , (10)
is a sufficient condition for the original “orthogonality” constraint (5). Thus, the original constraint
(5) can be simplified to (10), for each fixed β. The following iterative procedure will be used to
solve (9):
1. For fixed β, optimize the smooth g(·, ·) by solving:
argmin
g∈H(β)2
E
[
(Y − g(β>X,A))2], (11)
subject to the constraint (10).
2. For fixed g, optimize the coefficient β ∈ Θ by minimizing the squared error criterion of (11).
3. Iterate steps (1) and (2) until convergence with β ∈ Θ.
The data version of optimizing (g, β) can be derived as an empirical counterpart of the iterative
procedure given above. Details on implementing this algorithm are given below.
3 Estimation
3.1 Representation of link surface
Suppose we have observed data (Yi, Ai, Xi) (i = 1, . . . , n). For each candidate vector β ∈ Θ, let
ηi = η
(β)
i = β
>Xi (i = 1, . . . , n),
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where (on the left-hand side), for the notational simplicity, we suppress the dependence of the
linear predictor η(β) ∈ R on the candidate vector β.
Eilers and Marx (2003) have used tensor products of B-splines (de Boor, 2001) to represent
two-dimensional surfaces, which they termed tensor product P -splines, with separate difference
penalties applied to the coefficients of the B-splines along the covariate axes. Although alternative
nonparametric methods could also be used to estimate the smooth function g ∈ H(β)2 given each
coefficient vector β in model (4), in this paper we focus on one smoother, the tensor-product
P-splines, for the ease of presentation.
Specifically, for each η = β>X, to represent the 2-dimensional function g(η, A) in (11), we
consider the tensor product of the two sets of univariate cubic B-spline basis functions, say B and
Bˇ, with N (and Nˇ) B-spline knots for the basis functions that are placed along the η (and A) axis.
The number of knots N (and Nˇ) is chosen to be large, i.e., to allow the surface much flexibility.
Associated with the basis representation defined by the marginal basis function B (resp., Bˇ) is
an N ×N (resp., Nˇ × Nˇ) roughness penalty matrix, which we denote by P (and Pˇ). The penalty
matrix P (and Pˇ) can be easily constructed, for example, based on a second-order difference matrix
(e.g, see Eilers and Marx (2003)).
For each fixed ηi = β
>Xi (i = 1, . . . , n), let us write the n×N (and n×Nˇ) B-spline evaluation
matrix B (and Bˇ), in which its ith row is Bi = B(ηi)
> (and Bˇi = Bˇ(Ai)>). For a given knot
grid, a flexible surface can be approximated (Marx, 2015) at n points (ηi, Ai) (i = 1, . . . , n):
g(ηi, Ai) =
N∑
r=1
Nˇ∑
s=1
Br(ηi)Bˇs(Ai)γrs = (Bi ⊗ Bˇi)θ (i = 1, . . . , n), (12)
where the vector θ =
(
γ11, . . . , γ1Nˇ ; . . . ; γN1, . . . , γNNˇ
)> ∈ RNNˇ corresponds to an unknown (vec-
torized) coefficient vector of the tensor product representation of g, and ⊗ represents the usual
Kronecker product. Equation (12) can be compactly written as:
vec
{
g(ηi, Ai)
}
= g(ηn×1, An×1) = Dθ, (13)
where
D = BBˇ =
(
B ⊗ 1>
Nˇ
) (1>N ⊗ Bˇ) , (14)
in which the symbol  denotes element-wise multiplication of matrices. In Wood (2017), the
symbol  in (14) is called the row-wise Kronecker product, which results in a n × NNˇ tensor
product design matrix D from the two marginal design matrices B and Bˇ.
Similarly, the roughness penalty matrices associated with the tensor product representation
(12) can be constructed from the roughness penalty matrices P and Pˇ associated with the univariate
(marginal) basis matrices B and Bˇ, and are given by P = P⊗ INˇ and Pˇ = IN ⊗ Pˇ, for the axis
directions η and A, respectively. Here, I denotes the identity matrix, and both P and Pˇ are
square matrices with dimension NNˇ .
We now need to impose the constraint (10) on the 2-dimensional smooth function g under the
tensor product representation (13). For each fixed β, the constraint (10) on g amounts to excluding
the main effect of η = β>X from the function g. We deal with this by a reparametrization of the
representation (13) for g.
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Consider the following sum-to-zero (over the n observed values) constraint for the marginal
function of A:
1>Bˇγˇ = 0, (15)
for any arbitrary γˇ ∈ RNˇ , where 1 is a length n vector of 1’s. With constraint (15), the linear
smoother associated with the basis matrix Bˇ cannot reproduce constant functions (Hastie and
Tibshirani, 1999). That is, the linear constraint (15) removes the span of constant functions from
the span of the marginal basis matrix Bˇ associated with A. Constraint (15) results in a tensor
product basis matrix, D = BBˇ in (13), that will not include the main effect of η that results
from the product of the marginal basis matrix B with the constant function in the span of the
other marginal basis matrix Bˇ. Therefore, the resultant fit, under representation (13) (subject to
(15)) of the smooth function g, excludes the main effect of η. See Section 5.6 of Wood (2017) for
some more details.
We impose the linear constraint (15) on the matrix Bˇ, and consequently, the resulting basis
matrix D of representation of g in (13) becomes independent of the basis associated with the main
effect of η. Imposition of such a linear constraint (15) on a basis matrix is routine. The key is to
find an (orthogonal) basis for the null space of the constraint (15), and then absorb the constraint
into the basis construction (14). To be specific, we can create a Nˇ × (Nˇ − 1) matrix, which we
denote as Z, such that, given any arbitrary coefficient vector γˇ0 ∈ RNˇ−1, if we set γˇ = Zγˇ0,
then we have 1>Bˇγˇ = 0, and thus automatically satisfy the constraint (15). Such a matrix
Z is constructed using a QR decomposition of Bˇ>1. Then we can reparametrize the marginal
function of A by setting its model matrix to Bˇ ← BˇZ (and its penalty matrix to Pˇ ← Z>PˇZ).
From this point forward, for notational simplicity, we redefine the matrix Bˇ (and Pˇ) to be this
reparameterized constrained marginal basis matrix (and the reparameterized constrained penalty
matrix).
This sum-to-zero reparametrization of the marginal basis matrix Bˇ of A to satisfy (15) is simple
and creates a term vec
{
g(ηi, Ai)
} ∈ Rn in (13) that specifies such a pure A-by-X interaction (plus
the A main effect) component, that is also orthogonal to the X main effect. In Wood (2006), this
reparameterization approach is used to create an analysis of variance (ANOVA) decomposition
of a smooth function of several variables. In this paper we use this same reparameterization to
orthogonalize the interaction effect component g(β>X,A) from the main effect, and to allow an
unspecified/misspecified main effect for X in the estimation of the SIMSL (4). Provided that the
orthogonality constraint (i.e., (15)) issue is addressed, the interaction effect term g(β>X,A) of
model (4), for each fixed β, can be represented using penalized regression splines and estimated
based on penalized least squares, which we describe next.
3.2 Estimation algorithm
We define the criterion function for estimating (g, β) in the SIMSL (4):
Q(θ, β) = ‖Yn×1 − g(Xβ,An×1)‖2 + λ‖Pθ‖2 + λˇ‖Pˇ θ‖2
= ‖Yn×1 −Dθ‖2 + λ‖Pθ‖2 + λˇ‖Pˇ θ‖2
(16)
subject to the constraint that g(·, ·) satisfies (5). In (16), X is a n × p matrix whose ith row is
X>i . Since both θ and β are unknown in (16), estimation of θ and β is conducted iteratively. We
describe below the estimation procedure.
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1. For a fixed estimate of β (that defines the linear predictor η), minimize the following criterion
function over θ ∈ RNNˇ ,
‖Yn×1 −Dθ‖2 + λ‖Pθ‖2 + λˇ‖Pˇ θ‖2, (17)
where D is given by (14). Given tuning parameters (λ, λˇ), the minimizer θˆ of (17) is:
θˆ =
(
D>D + λP>P + λˇPˇ>Pˇ
)−1
D>Yn×1.
2. For a fixed estimate of the surface g (i.e., given θ), perform a first-order Taylor approximation
of g(Xβ,An×1) in (16) with respect to β, around the current estimate, denote as β˜ ∈ Θ,
g(Xβ,An×1) ≈ g(Xβ˜, An×1) + diag
{
g˙∂1(Xβ˜, An×1)
}
X(β − β˜), (18)
where g˙∂1(u, a) denotes the partial first derivative of g(u, a) with respect to the first variable
u, i.e., ∂g(u,a)
∂u
. Utilizing (18), the quadratic loss term in (16), as a function of β given θ, can
be approximated as:∥∥∥Yn×1 − g(Xβ˜, An×1)− diag{g˙∂1(Xβ˜, An×1)}X(β − β˜)∥∥∥2
=
∥∥∥Yn×1 − g(Xβ˜, An×1) + diag{g˙∂1(Xβ˜, An×1)}Xβ˜ − diag{g˙∂1(Xβ˜, An×1)}Xβ∥∥∥2
=
∥∥Y ∗n×1 −X∗β∥∥2 ,
(19)
where Y ∗n×1 = Yn×1−g(Xβ˜, An×1)+diag
{
g˙∂1(Xβ˜, An×1)
}
Xβ˜, andX∗ = diag
{
g˙∂1(Xβ˜, An×1)
}
X.
The minimizer βˆ of (19) is:
βˆ =
(
X∗>X∗
)−1
X∗>Y ∗n×1.
Then we scale βˆ to unit L2 norm, i.e., βˆ/‖βˆ‖, and enforce a positive first element to restrict
the estimate of β to be in Θ.
These two steps can be iterated until convergence to obtain an estimate of (g∗, β∗) in (9), which
we denote as (gˆ∗, βˆ∗). For Step 1, the tuning parameters (λ, λˇ) can be automatically selected, for
example, by the generalized cross-validation (GCV) or the restricted maximum likelihood (REML)
methods. In this paper, we use REML for the simulation examples and the applications.
Lastly, for model hierarchy, it is common practice to include all lower order effects of variables
if there are higher-order interaction terms including that set of variables. Once convergence of the
estimate βˆ∗ is reached in the above algorithm and the single-index β>X in the term g(β>X,A) of
model (4) is estimated, we recommend fitting one final (unconstrained) smooth function g of A and
βˆ∗>X, without enforcing the constraint (15) on g. Given the final estimate of β, the unconstrained
final surface-link g(·, ·) retains the main effect of β>X and preserves model hierarchy.
4 Extension to a generalized single-index regression for
modeling interactions
The proposed approach to optimizing the interaction effect term of model (4) can be extended to
a more general setting in which the response Y follows an exponential family distribution given
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X ∈ X and A ∈ A. We again assume an additive single-index model (4) for the true mean
response function:
E[Y |X,A] = µ0(X) + g0(β>0 X,A), (20)
where the term µ0(X) represents an unspecified main effect of X, and the term g0(β
>
0 X,A) rep-
resents the A-by-X interaction effect. (In this section, we use subscript (0) to indicate the “true”
value.) In (20), for model identifiability, we set β0 ∈ Θ and E
[
g0(β
>
0 X,A)|X
]
= 0 separating the
X main effect from the A-by-X interaction effect. The functions µ0 ∈ H1 and g0 ∈ H(β0)2 in (20)
are assumed to be appropriately defined to give a valid range for the mean of Y , given X and A
(e.g., for a Bernoulli Y , the mean response function E[Y |X,A] must satisfy 0 ≤ E[Y |X,A] ≤ 1,
almost surely).
To approximate the A-by-X interaction effect term g0(β
>
0 X,A) in (20) in the presence of the
unspecified X main effect term µ0(X), we propose to utilize the following working model, without
including a term that corresponds to the X main effect component µ0(X) in (20):
E[Y |X,A] ≈ h−1(g(β>X,A)), (21)
subject to the constraint E[g(β>X,A)|X] = 0, where h(·) = b˙−1(·) (in which b˙(·) is the first
derivative of b(·)) is the canonical link function associated with the assumed exponential family
distribution, which is specified by an exponential family density of the form:
exp
{[
Y g(β>X,A)− b(g(β>X,A))]/a(φ) + c(Y, φ)} , (22)
with g ∈ H(β)2 and β ∈ Θ. In (22), φ is an arbitrary “scale” parameter, and the functions a, b and
c are distribution-specific known functions. We propose to optimize the working model (21) by
solving for the constrained maximizer (g∗, β∗):
(g∗, β∗) = argmax
g∈H(β)2 ,β∈Θ
E
[
Y g(β>X,A)− b(g(β>X,A))]
subject to E
[
g(β>X,A)|X] = 0 (23)
where the expectation in the criterion function is with respect to (Y,A,X), in which their rela-
tionships are specified by the mean model (20). In (23), b(u) = u2/2 for a Gaussian Y (for which
the optimization (9) is a special case of (23)), b(u) = log{1 + exp(u)} for a Bernoulli Y , and
b(u) = exp(u) for a Poisson Y . The solution (g∗, β∗) of (23) is thus defined as the minimizer of
the Kullback-Leibler divergence between the working model (21) and the true model (20).
The constraint E
[
g(β>X,A)|X] = 0 in optimization (23) implies:
E
[
Y g(β>X,A)− b(g(β>X,A))] = E [{µ0(X) + g0(β>0 X,A)}g(β>X,A)− b(g(β>X,A))]
= E
[
E
[
µ0(X)g(β
>X,A)|X]]+ E[g0(β>0 X,A)(g(β>X,A)− b(g(β>X,A))]
= E
[
g0(β
>
0 X,A)(g(β
>X,A)− b(g(β>X,A))],
(24)
which is independent of µ0(X) in model (20). Therefore, the solution (g
∗, β∗) for the optimization
problem (23) is given independently of the true “main” effect term µ0(X) in (20). This indepen-
dence enables us to focus only on the A-by-X interaction effect term of model (20) if our interest
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is in the interaction effect term, without having to correctly specify or include the X main effect
term in the estimation. From the right-hand side of (24), we can derive how the solution (g∗, β∗)
of optimization (23) is related to (g0, β0) of the true mean model (20).
Proposition 1 The solution (g∗, β∗) of the constrained optimization problem (23) satisfies:
g0 = h
−1 ◦ g∗ and β0 = β∗, (25)
where g0 ∈ H(β0)2 and β0 ∈ Θ are given from the true mean model (20). In (25), the function h−1
is the inverse of the canonical link associated with the assumed exponential family distribution and
the operator ◦ represents the composition of two functions.
The proof of Proposition 1 is in the Supplemental Materials. In (25), h−1(u) = u (the identity
function) for a Gaussian Y , h−1(u) = exp(u)/{1+exp(u)} for a Bernoulli Y , and h−1(u) = exp(u)
for a Poisson Y .
Given data (Yi, Ai, Xi) (i = 1, . . . , n), for each fixed β ∈ Θ, the profile estimator of the function
g on the right-hand side of (23) can be obtained by implementing a standard generalized additive
model (GAM) fitting procedure (e.g., Hastie and Tibshirani (1999)) that bases on iteratively re-
weighted least squares (IRLS), with representation (13) to approximate g; the only adjustment to
be made to the standard GAM fitting procedure is to enforce the constraint E[g(β>X,A)|β>X] = 0
on the smooth g. As in Section 3.1, this constraint can be absorbed into the tensor product basis
representation (13) in the estimation. Given the finite dimensional representation (13) for g,
the squared error term in (17) is replaced by an empirical version of the negative of the criterion
function in (23). The same iterative procedure alternating between the estimation of θ ∈ RNNˇ and
the estimation of β ∈ Θ can be performed until convergence of βˆ, as in Section 3.2. The resulting
estimate of (g∗, β∗) in (23) can be used to estimate (g0, β0) in (20), based on the relationship (25).
In the Supplemental Materials, we provide an example illustrating the approach (23) to mod-
eling interaction effects between X and A on a discrete-valued response Y .
5 Simulation example
In this section, we consider a set of simulation studies with data generated from the four sce-
narios described in Chen et al. (2016). We generate p-dimensional vectors of covariates, X =
(X1, . . . , Xp)
>, where each entry is generated independently from Uniform[−1, 1]. In Scenarios 1
and 2, the treatment A is generated from Uniform[0, 2] independently of X, mimicking a random-
ized trial. In Scenarios 3 and 4, the distribution of A (described below) depends on X, mimicking
an observational study setting. In each scenario, the outcome Y , given X and A, is generated
from a normal distribution with unit variance, with the following four different mean function
scenarios:
1. Scenario 1: E[Y |X,A] = 8 + 4X1 − 2X2 − 2X3 − 25(fopt(X) − A)2, where fopt(X) = 1 +
0.5X1 + 0.5X2. Here, the optimal individualized dose rule is a linear function of X.
2. Scenario 2: E[Y |X,A] = 8 + 4 cos(2piX2)− 2X4 − 8X35 − 15|fopt(X)− A|, where
fopt(X) = 0.6(−0.5 < X1 < 0.5)+1.2(X1 > 0.5)+1.2(X1 < −0.5)+X24 +0.5 log(|X7|+1)−0.6.
Here, the optimal individualized dose rule is a nonlinear function of X.
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3. Scenario 3 is the same as in Scenario 2, except that the distribution of A depends on X as
follows:
A ∼
{
TruncN (−0.5 + 0.5X1 + 0.5X2, 0, 2, 0.5) , when X3 < 0
TruncN (|0.5 + 1.5X2| , 0, 2, 1) , when X3 > 0
where TruncN (µ, a, b, σ) denotes the truncated normal distribution with mean µ, lower
bound a and upper bound b, and standard deviation σ.
4. Scenario 4 is the same as in Scenario 2, except that the distribution of A depends on X as
follows:
A ∼ TruncN (fopt(X), 0, 2, 0.5) .
Following Chen et al. (2016), we set p = 30 in Scenario 1, and p = 10 for Scenarios 2, 3 and 4.
For each simulated dataset, we apply the proposed method of estimating the A-by-X interactions
using the SIMSL (4) and estimating the optimal dose rule fopt by fˆ(X) = argmax
a∈A
gˆ∗(βˆ∗>X, a).
The main effect estimate µˆ∗(X) in (8) is simply taken to be 0. We simulated 200 data sets for
each scenario. For comparison, we report results of the estimation approaches considered in Chen
et al. (2016), including their Gaussian kernel-based outcome-weighted learning (K-O-learning) and
linear kernel-based outcome-weighted learning (L-O-learning). We also report a support vector
regression (SVR; Vapnik, 1995; Smola and Scholopf, 2004) with a Gaussian kernel to estimate the
nonlinear relationship between Y and (A,X) (Zhao et al., 2009) that was used for comparison. In
Scenario 1, we used (A,X) as the covariates for the outcome in the SIMSL. In Scenarios 2, 3 and
4, we used (A,X,X2) (i.e., including a quadratic term in X) as the covariates for the SIMSL.
Since we are simulating data from known models in which the true relationship E[Y |X,A] is
known, we can compare the estimated dose rules fˆ derived from each method in terms of the
value (1). Specifically, an independent test set of size n˜ = 5000 was generated and the value
(1) of fˆ was approximated using Vˆ(fˆ) = n˜−1∑n˜i=1 E[Yi|Xi, Ai = fˆ(Xi)], for each simulation run.
Given each scenario and a training sample size n, we replicate the simulation experiment 200
times, each time estimating the value. Again, following Chen et al. (2016), we report the averaged
estimated values (and standard deviations) for the cases where fˆ is estimated from a training set
of size n = 50, 100, 200, 400 and 800 for Scenario 1 and 2, and the cases with n = 200 and 800 for
Scenario 3 and 4. The simulation results are given in Table 1 and 2.
The results in Table 1 and 2 indicate that the proposed regression method for optimizing indi-
vidualized dose rules outperforms the alternative approaches presented in Chen et al. (2016) in all
cases except when the training sample size is very small (n = 50). In Table 2, K-O-learning(Prp)
refers to the propensity score-adjusted K-O-learning of Chen et al. (2016). When the sample size is
very small, the outcome-weighted learning approaches outperform the regression-based approaches
(SIMSL and SVR), especially for Scenario 1 (with p = 30) where the regression approaches exhibit
large variances. However, when n = 100, the performance of the SIMSL approach improves dra-
matically in terms of both value and small variance. We also note that using (A,X,X2) instead of
(A,X) in Scenario 2 leads to a substantial improvement in performance. If (X,A) is used for fitting
the SIMSL in Scenario 2, the estimated values are: −7.16(6.34),−2.04(4.81), 1.90(2.21), 3.68(1.07)
and 4.44(0.91), for sample sizes n = 50, 100, 200, 400 and 800, respectively.
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n SIMSL K-O-learning L-O-learning SVR
Scenario 1 50 -0.19 (5.05) 4.78 (0.48) 4.83 (1.40) -12.21 (7.53)
100 7.00 (0.61) 5.69 (0.40) 5.39 (0.93) -2.57 (6.34)
200 7.67 (0.13) 6.68 (0.26) 6.85 (0.34) 3.46 (1,97)
400 7.85 (0.05) 7.28 (0.15) 7.41 (0.14) 6.13 (0.47)
800 7.92 (0.02) 7.54 (0.08) 7.67 (0.08) 7.36 (0.12)
Scenario 2 50 -0.11 (2.38) 2.00 (0.29) 1.16 (0.71) -1.96 (1.70)
100 3.39 (1.04) 2.19 (0.43) 1.57 (0.52) 0.24 (1.42)
200 4.68 (0.43) 2.84 (0.37) 2.02 (0.30) 2.01 (0.84)
400 5.26 (0.18) 3.69 (0.27) 2.30 (0.18) 3.47 (0.37)
800 5.58 (0.10) 4.41 (0.19) 2.49 (0.10) 4.35 (0.19)
Table 1: Average (and sd) value Vˆ(f) from 200 replicates from the randomized trial scenarios. In
both settings, the oracle fopt attains a value function V(fopt) = 8 (boldface denotes the largest in
each row).
n SIMSL K-O-learning K-O-learning(Prp) SVR
Scenario 3 200 4.01 (1.01) 2.68 (0.30) 2.74 (0.29) 1.99 (0.83)
800 5.43 (0.26) 4.06 (0.30) 4.19 (0.20) 4.09 (0.28)
Scenario 4 200 3.55 (1.08) 3.29 (0.28) 3.23 (0.28) -0.95 (1.57)
800 5.24 (0.24) 4.91 (0.14) 4.73 (0.17) 3.04 (0.52)
Table 2: Average (and sd) value Vˆ(f) from 200 replicates from observational studies. In both
settings, the oracle fopt attains a value function V(fopt) = 8 (boldface denotes the largest in each
row).
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6 Application to optimization of the warfarin dose with
clinical and pharmacogenetic data
In this section, the utility of the SIMSL approach to personalized dose finding is illustrated from
an anticoagulant study. Warfarin is a widely used anticoagulant to treat and prevent blood clots.
The therapeutic dosage of warfarin varies widely across patients and its administration must be
closely monitored to prevent adverse side effects. Our analysis of the data will broadly follow
that of Chen et al. (2016). After removing patients with missing data, the dataset provided by
International Warfarin Pharmacogenetics Consortium et al. (2009) (publicly available to download
from https://www.pharmgkb.org/downloads/) consists of 1780 subjects, including information on
patient covariates (X), final therapeutic dosages (A), and patient outcomes (INR, International
Normalized Ratio). INR is a measure of how rapidly the blood can clot. For patients prescribed
warfarin, the target INR is around 2.5. In order to convert the INR to a measurement responding
to the warfarin dose level, we construct an outcome Y = −|2.5− INR|, and a larger value of Y is
considered desirable.
There were 13 covariates X = (X1, . . . , X13)
> in the dataset (both clinical and pharmacogenetic
variables): height (X1), weight (X2), age (X3), use of the cytochrome P450 enzyme inducers (X4;
the enzyme inducers considered in this analysis includes phenytoin, carbamazepine, and rifampin),
use of amiodarone (X5), gender (X6; 1 for male, 0 for female), African or black race (X7), Asian race
(X8), the VKORC1 A/G genotype (X9), the VKORC1 A/A genotype (X10), the CYP2C9 *1/*2
genotype (X11), the CYP2C9 *1/*3 genotype (X12), and the other CYP2C9 genotypes (except
the CYP2C9 *1/*1 genotype which is taken as the baseline genotype) (X13). Further details on
these covariates are given in International Warfarin Pharmacogenetics Consortium et al. (2009).
The first 3 covariates (height, weight, age) were treated as continuous variables, standardized to
mean zero and unit variance; the other 10 covariates are indicator variables.
In estimating the optimal individualized dose rule fopt, modeling the drug (dose level A)
interactions with the patient covariates X in their effects on Y is essential. Under the proposed
SIMSL approach (4), the A-by-X interaction effect term g(β>X,A) is the target component of
interest, whereas the X main effect term µ(X) is a “nuisance” component, since the optimal dose
rule fopt does not depend on µ(X). To estimate the SIMSL (4), we first approximate the solution
(8) of the main effect term µ(X) of (4), by utilizing an additive working model. This working
model consists of a set of linear (parametric) terms for the discrete covariates X4, . . . , X13 and a
set of cubic P -spline smooth terms for the continuous covariates X1, X2 and X3, estimated by
penalized least squares, with their smoothing parameters estimated by REML. Then, based on
the residual Y˜ = Y − µˆ∗(X), we approximate the solution (9) of the A-by-X interaction effect by
the procedure described in Section 3.
The estimated β is (0.18, 0.02,−0.02, 0.52,−0.41, 0.10,−0.23, 0.32,−0.11, 0.05, 0.02,−0.34,−0.48)>.
The third panel in Figure 1 displays the estimated interaction surface plot of the 2-dimensional
surface-link function g(β>X,A) of model (4), showing an interactive relationship on the index-
treatment domain. The first two panels in Figure 1 display the plots for the estimated individual
smooth function of the dose A and that of the estimated single-index β>X, where the individ-
ual smooths are obtained from fitting additive models with two univariate cubic P -spline smooth
terms (associated with A and β>X, respectively).
Due to the restriction β ∈ Θ on the single-index coefficient, building confidence intervals for
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β is complicated. In particular, the positivity constraint (β1 > 0) imposed on the estimate of
β1 will force the signs of the other single-index coefficient estimates of β2, . . . , βp to switch if the
sign of β1 is initially estimated to be negative. Especially when β1 ≈ 0, the variability of the
estimates of β2, . . . , βp across (bootstrap) resampled datasets due to their sign switches can be
rather dramatic. Therefore, based on a bootstrap approach, instead of estimating the variance
of βˆj, we estimate the variance of the more robust measure |βˆj|, which quantifies the magnitude
of contribution of each covariate Xj to the heterogeneous dose responses captured by the model
g(β>X,A). If we can reasonably assume that the sign of βˆj correctly estimates that of βj, i.e.,
if sign(βˆj) = sign(βj), then var(βˆj) = var(|βˆj|). As a heuristic, for this example, we use the
approximation, var(βˆj) ≈ var(|βˆj|), to build an approximate 95% normal confidence interval for
βj,
(
βˆj − 1.96
√
var(|βˆj|), βˆj + 1.96
√
var(|βˆj|)
)
, where var(|βˆj|) is estimated from 500 bootstrap
resampled datasets.
The approximate 95% bootstrap confidence intervals for the βj’s associated with the covariates
height (X1), the use of the cytochrome P450 enzyme inducers (X4), the use of amiodarone (X5),
the CYP2C9 *1/*3 genotype (X12), and the other CYP2C9 genotypes (X13) do not include 0. We
infer that these covariates are potentially clinically important drug effect modifiers, interacting
with warfarin in their effects on INR.
Chen et al. (2016) noted that the analysis results from International Warfarin Pharmacogenet-
ics Consortium et al. (2009), as well as their linear kernel-based outcome-weighted learning results,
suggest increasing the dose if patients are taking Cytochrome P450 enzyme (X4) and decreasing
the dose if patients are taking Amiodarone (X5). Roughly speaking, the interaction surface (the
right-most panel) in Figure 1 indicates that for a larger value of β>X (e.g., β>X > 0), a larger
value of A (e.g., A > 60) will generally be preferred, whereas for a small value of β>X, a lower
dose level for A (e.g., A < 40) will generally be preferred. Considering the sign of the coefficient
estimates associated with X4 (βˆ4 = 0.52) and X5 (βˆ5 = −0.41), this is roughly consistent with In-
ternational Warfarin Pharmacogenetics Consortium et al. (2009) and Chen et al. (2016). However,
the non-monotone interaction surface indicates that this dose suggestion should also be exercised
with care.
To evaluate the performance of the individualized dose rules estimated from the 6 methods,
including the propensity score-adjusted outcome-weighted learning with a linear/Gaussian kernel,
denoted as L-O-learning(Prp) and K-O-learning(Prp), respectively) considered in Section 5, we
randomly split the dataset at a ratio of 1-to-1 into a training set and a testing set, replicated 100
times, each time estimating fopt using the 6 methods based on the training set, and estimating the
value (1) of each estimated fopt based on the testing set. Unlike the simulated data in Section 5,
the true relationship between the covariate-specific dose and the response is unknown. Therefore,
for each dose rule f , we need to estimate the value (1) from the testing data. Given a dose rule
f , only a very small proportion (or none) of the observations will satisfy Ai = f(Xi), and thus
only a very small proportion (or none) of the observations in the testing data will contribute
information to estimate the value (1). However, Cai and Tian (2016) noted that the value (1) for
each f can also be written as V(f) = E[E[Y |A = f(X), f(X)]]. Therefore, using a 2-dimensional
smoother of A and f(X) for Y , one may first obtain a nonparametric estimate of E[Y |A, f(X)],
denoted as mˆ(A, f(X)), and then V(f) may be estimated as Vˆ(f) = n−1∑ni=1 mˆ(f(Xi), f(Xi)).
Specifically, given a dose rule f estimated from a training set, we can estimate E[Y |A, f(X)] based
13
Figure 1: Estimated individual effects, g1 (left panel) and g2 (middle panel), for the additive
model E[Y |β>X,A] = g1(A)+g2(β>X), conditioning on the estimated single-index variable β>X.
The third panel: Estimated link surface, g(β>X,A), for the covariates (β>X) and warfarin (A)
interaction; the red and green surfaces are at plus or minus one standard error from the estimated
(the black) surface in the middle.
on (Yi, Ai, f(Xi)) from a test set, using a set of thin plate regression spline bases obtained from a
rank-100 eigen-approximation to a thin plate spline, with the smoothness parameter selected by
REML, implemented via the R (R Core Team, 2019) function mgcv::gam (Wood, 2019b). A thin
plate spline is an isotropic smooth; isotropy is often appropriate for two variables observed on the
same scale, which is the case here.
Figure 2 displays a boxplot describing the distributions for the estimated values (1) of the 6
estimation methods described in Section 5, obtained from the aforementioned 100 random train-
ing/testing splits. The boxplots indicate that the proposed SIMSL method and the propensity-
score adjusted K-O-learning of Chen et al. (2016) perform at a similar level, while outperforming
all other approaches. This illustrates the potential utility of the proposed regression approach to
optimizing individualized dose rules. In comparison to the outcome-weighted learning approach
of Chen et al. (2016), one advantage of the proposed approach is that it allows visualization of
the estimated interactive structure on the dose-index domain as illustrated in the right panel of
Figure 3. Additionally, if each of the covariates is standardized to have, say, unit variance, then
the relative importance of each covariate in characterizing the heterogeneous dose response can
be determined by the magnitude of the estimated coefficients in β, rendering a potentially useful
interpretation when examining the drug-covariates interactions.
7 Discussion
In this paper, we proposed a variant of a single-index model that utilizes a surface link-function
as a function of a linear projection of covariates and a continuous “treatment” variable. This
single index model with a surface link can effectively estimate the effect on a response of possibly
nonlinear interactions between a set of covariates and the treatment variable defined on a contin-
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Figure 2: Boxplots of the estimated values of the individualized dose rules using 6 approaches,
obtained from 100 randomly split testing sets. Mean (and sd) of the value estimates: SIMSL
(-0.227 (0.03)) SVR: -0.256 (0.02); L-O-learning(Prp): -0.274 (0.01); K-O-learning(Prp): -0.234
(0.03); L-O-learning: -0.274 (0.01); K-O-learning: -0.279 (0.01).
uum. The proposed regression model is useful for developing personalized dose rules in precision
medicine, and more generally, in a situation where we are particularly interested in modeling in-
teractions between a set of covariates and a real-valued predictor of interest. The model gives a
simple, intuitive and straightforward method of modeling smooth interactions, without the need
for a significant change in the established generalized additive regression modeling framework.
In many applications, only a subset of variables may be useful in determining an optimal
individualized dose rule. Also, high-dimensional settings can lead to instabilities and issues of
overfitting. Forthcoming work will introduce a regularization method that can both avoid over-
fitting and choose among multiple potential covariates by obtaining a sparse estimate of the
single-index coefficient β. Future extensions of this work could also include an extension of the
proposed regression to a multiple-index regression for modeling interactions and the incorporation
of a functional covariate.
SUPPLEMENTAL MATERIALS
Supporting Information: a pdf file containing the proof of Proposition 1 and a data analy-
sis example illustrating an application of the generalized single-index regression approach
described in Section 4.
R-package for SIMSL routine: R-package simsl (Park et al., 2019) available on CRAN con-
taining code to perform the proposed single-index regression method, and the datasets and
the simulation examples illustrated in this article.
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SUPPLEMENTARY MATERIAL
A Proof of Proposition 1
Let Q(g, β) = E
[
Y g(β>X,A) − b(g(β>X,A))] in (23) of the main manuscript, where the expec-
tation is with respect to (Y,A,X), in which their relationships are specified by the mean model
(20) of the main manuscript. We have
Q(g, β) = E
[{µ0(X) + g0(β>0 X,A)}g(β>X,A)− b(g(β>X,A))]
= E
[
EA|X
[{µ0(X) + g0(β>0 X,A)}g(β>X,A)− b(g(β>X,A)) | X]]
= E
[
EA|X
[
µ0(X)g(β
>X,A) + g0(β>0 X)g(β
>X,A)− b(g(β>X,A)) | X]]
= E
[
g0(β
>
0 X,A)g(β
>X,A)− b(g(β>X,A))]
= E
[
E
[
g0(β
>
0 X,A)g(β
>X,A)− b(g(β>X,A)) | β>X,A]]
= E
[
E
[
g0(β
>
0 X,A)|β>X,A
]
g(β>X,A)− b(g(β>X,A))],
(26)
where the second equality is from an application of the iterated expectation rule to condition on
X, and the fourth equality is from: EA|X [µ0(X)g(β>X,A)|X] = µ0(X)EA|X [g(β>X,A)|X] = 0, as
a result of the constraint in (23) of the main manuscript that we impose on g. Notice that Q(g, β)
in (26) is independent of the “nuisance” term µ0(X).
Given each β and the corresponding variables (β>X,A), we have
∂Q(g, β)
∂g
= E
[
g0(β
>
0 X,A)|β>X,A
]− b˙(g(β>X,A)), (27)
and setting the right-hand side of equation (27) to 0 implies that, given each β and the corre-
sponding variables (β>X,A), the maximizer g(β>X,A) of the right-hand side of (23) of the main
manuscript should satisfy the stationary condition:
b˙(g(β>X,A)) = E
[
g0(β
>
0 X,A)|β>X,A
]
,
or equivalently:
g(β>X,A) = b˙−1(E
[
g0(β
>
0 X,A)|β>X,A
]
). (28)
Notice that the maximizer (28) depends only on g0(β
>
0 X,A) and not on µ0(X). Given each β and
the corresponding variables (β>X,A), we profile out the term g(β>X,A) in the last line of (26) by
its maximizer (28), which results in the following profile objective function, free of the unknown
g:
E
[
E
[
g0(β
>
0 X,A)|β>X,A
]
b˙−1(E
[
g0(β
>
0 X,A)|β>X,A
]
)− b(b˙−1(E[g0(β>0 X,A)|β>X,A]))]. (29)
For (29), let us reparametrize for the sake of simplicity:
θ(β>X,A) = b˙−1(E
[
g0(β
>
0 X,A)|β>X,A
]
). (30)
Then, we can re-write (29) as:
E
[
E
[
g0(β
>
0 X,A)|β>X,A
]
θ(β>X,A)− b(θ(β>X,A))] = E[E[g0(β>0 X,A)θ(β>X,A)− b(θ(β>X,A))|β>X,A]]
= E
[
g0(β
>
0 X,A)θ(β
>X,A)− b(θ(β>X,A))].
(31)
18
The second line of (31) can be viewed as an expression of the negative of the cross-entropy (equiv-
alently, the Kullback-Leibler (KL) divergence) between an exponential family distribution with
the canonical parameter θ(β>X,A) in (30) (i.e., an exponential family distribution with the con-
ditional mean: b˙(θ(β>X,A)) = E
[
g0(β
>
0 X,A)|β>X,A
]
), and some “true” (reference) exponential
family distribution with the conditional mean: g0(β
>
0 X,A). It is clear that the maximizer, which
we denote as β∗, of the negative of the KL divergence (over β ∈ Θ) occurs at β∗ = β0 (at the
true distribution). Thus, the profile maximizer β∗ ∈ Θ of the profile objective function (29) is
given by β∗ = β0. Plugging β = β0 into (28) implies that the maximizer g∗ of the objective
function Q(g, β0) satisfies: g
∗(β>0 X,A) = b˙
−1(g0(β>0 X,A)), which results in the desired expression
of g∗ = h ◦ g0, since b˙−1 = h is the canonical link function.
B Application to estimation of a pollutant-season interac-
tion on mortality from air-pollution data
In this section, we consider a data analysis example illustrating an application of the generalized
single-index regression method (described in Section 4 of the main manuscript) that models in-
teractions between a set of predictors (X) and a variable (A) in their effects on a non-normal
response (counts) variable.
Several time series studies of air pollution and health have provided compelling evidence of
a positive association between short-term variation in ambient levels of particulate matter and
daily mortality counts (see, e.g., Pope et al., 1995; Dockery and Pope, 1996; Bell et al., 2004).
Peng and Dominici (2008) noted that the short-term effects of particulate matter on mortality
might exhibit seasonal (time) variation. In particular, the characteristics of the particulate matter
mixture can vary seasonally throughout the year. Patterns of human activity also change from
season to season, and as a result, an air pollution concentration in one season may lead to a
different effect in a different season. Other potential time-varying confounding and modifying
factors (such as temperature and influenza epidemics) can also impact effects of air pollution on
mortality differently in different seasons (Peng and Dominici, 2008). Therefore, the relationships
between mortality and air pollution levels can vary considerably across seasons. In this section,
we illustrate the utility of the SIMSL approach to estimating the interactions between seasonal
variation and particulate matter on their effects on mortality.
The data are from Peng and Welty (2004) and publicly available from the R (R Core Team,
2019) package gamair (Wood, 2019a). The response of interest is the daily number of deaths
in Chicago over 14 years. The outcomes Yt represent a time series of daily mortality counts
(indicating the number of deaths that occurred on day t), with the conditional mean, mt, that
depends on particulate matter levels and season. As typical for modeling time series of counts, we
assume a Poisson distribution for the counts Yt. To model seasonal variation, we introduce the
“day of a year” variable that ranges from 0 to 364, defined as At := t mod 365, in which At = 0
corresponds to the first calendar day of a year.
To study the pollutant-season interaction effects, we consider the following SIMSL (see model
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Figure 3: Estimated individual (i.e., marginal) effect functions, g1 (left panel) and g2 (center
panel), obtained by fitting the GAM: log(E[Y |β>X,A]) = g1(A) + g2(β>X), conditioning on the
estimated single-index β>X of the generalized SIMSL (21) of the main manuscript. The third
panel: Estimated link surface, g(·, ·) of the generalized SIMSL (21) of the main manuscript, for
the pollutant (β>X) and season (A) interaction; the red and green surfaces are at plus or minus
one standard error from the estimate (the black surface in the middle).
(20) of the main manuscript, for the identifiability condition imposed on g0):
mt = E[Yt|Xt, Xt−1, . . . , Xt−K , At] = µ0(Xt, Xt−1, . . . , Xt−K)+g0
(
K∑
j=0
βjXt−j, At
)
(t = 1, . . . , n)
(32)
where the single-index β>X is defined in terms of distributed lag model:
K∑
j=0
βjXt−j (t = 1, . . . , n)
where Xt ∈ R is the time series of daily (day t) particulate matter levels, and K is the maximum
lag. Hence, the model includes multiple lags of pollution, rather than the pollution level only on
the day t itself. This K-lagged model is reasonable, as any effects would likely take some time
to manifest themselves via the aggravation of existing medical conditions (Wood, 2017). This
accumulated particulate matter over K days enters into the function g0(·, ·) in model (32). The
coefficients βj ∈ R associated with this weighted sum need to be estimated from data, and we
are particularly interested in summarizing the variability in the lagged particulate matter levels
(Xt, Xt−1, . . . , Xt−K) that is related to the seasonal variation At in their effects on the outcome
Yt, rather than the “nuisance” variability unrelated to At. The function µ0 on the right-hand side
of (32) represents the pollutant “main” effect unrelated to At. Our focus is on estimating the
interaction effect term term of model (32) to study the pollutant-season interactions on mortality.
We estimate the pollutant-season interactions based on the working model (21) of the main
manuscript, with the logarithmic link h(·) = log(·):
log(mt) ≈ g(β>Xt, At) (t = 1, . . . , n) (33)
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subject to the constraint E[g(β>X,A)|X] = 0, in which X := (Xt, Xt−1, . . . , Xt−K)> and β :=
(β0, . . . , βK)
>, where we omit the subscript t in writing X and A, for notational simplicity. In
this illustration, we take K = 4. We model the seasonal effect to vary smoothly over the course
of a year, but we constrain the effect to be periodic across years. We accomplish this by utilizing
a set of cyclic cubic spline basis functions Bˇ (whose left and right ends match, up to a second
derivative) to define the model matrix Bˇ associated with the variable A (which is again subject
to the linear constraint (15) of the main manuscript, for the “orthogonality” condition), and use
this cyclic basis matrix Bˇ to construct the tensor product basis matrix D in (14) of the main
manuscript for representing g.
The single-index coefficient β in model (33) is estimated as (0.80, 0.54, 0.14, 0.17, 0.13)>. The
approximate 95% bootstrap confidence intervals (based on 500 bootstrap replications; see Sec-
tion 6 of the main manuscript for description of the approximate bootstrap confidence interval
construction procedure) associated with the lag 0 and the lag 1 (i.e., the first two elements of
β) particulate matter concentration levels do not include 0, indicating that (not surprisingly) the
particulate matter level on the day itself and one day prior are determined to be important for
modeling the pollutant-season interaction.
The estimated surface-link g(β>X,A) plot displayed in the right-most panel in Figure 3 indi-
cates that for a small value of β>X, the mortality is largely explained by the U-shaped individual
effect of the season (i.e., the variable A) (see the left-most panel in Figure 3), which exhibits
the usual pattern of a low mortality rate during the summer and a high mortality rate during
the winter. Moreover, the middle panel in Figure 3 indicates that mortality, not surprisingly,
increases monotonically with the accumulated particulate matter (β>X). However, the estimated
surface-link on the right-most panel in Figure 3 visualizes the pollutant-season interactions on
mortality, which indicates that the effect the accumulated particulate matter (β>X) has a larger
effect in the spring (e.g., around A = 100) and smaller effects in the other seasons (e.g., around
A = 300), showing an interesting pollutant-season interaction pattern. In particular, for a large
value of β>X (say, β>X > 2) the contribution of the accumulated particulate matter (β>X) on
mortality in the spring time (around A = 100) can be quite substantial.
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